Literature DB >> 17999389

Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis.

Stephen J Freedland1, John Mavropoulos, Amy Wang, Medha Darshan, Wendy Demark-Wahnefried, William J Aronson, Pinchas Cohen, David Hwang, Bercedis Peterson, Timothy Fields, Salvatore V Pizzo, William B Isaacs.   

Abstract

BACKGROUND: Recent evidence suggests carbohydrate intake may influence prostate cancer biology. We tested whether a no-carbohydrate ketogenic diet (NCKD) would delay prostate cancer growth relative to Western and low-fat diets in a xenograft model.
METHODS: Seventy-five male SCID mice were fed a NCKD (84% fat-0% carbohydrate-16% protein kcal), low-fat (12% fat-72% carbohydrate-16% protein kcal), or Western diet (40% fat-44% carbohydrate-16% protein kcal). Low-fat mice were fed ad libitum and the other arms fed via a modified-paired feeding protocol. After 24 days, all mice were injected with LAPC-4 cells and sacrificed when tumors approached 1,000 mm(3).
RESULTS: Despite consuming equal calories, NCKD-fed mice lost weight (up to 15% body weight) relative to low-fat and Western diet-fed mice and required additional kcal to equalize body weight. Fifty-one days after injection, NCKD mice tumor volumes were 33% smaller than Western mice (rank-sum, P = 0.009). There were no differences in tumor volume between low-fat and NCKD mice. Dietary treatment was significantly associated with survival (log-rank, P = 0.006), with the longest survival among the NCKD mice, followed by the low-fat mice. Serum IGFBP-3 was highest and IGF-1:IGFBP-3 ratio was lowest among NCKD mice while serum insulin and IGF-1 levels were highest in Western mice. NCKD mice had significantly decreased hepatic fatty infiltration relative to the other arms.
CONCLUSIONS: In this xenograft model, despite consuming more calories, NCKD-fed mice had significantly reduced tumor growth and prolonged survival relative to Western mice and was associated with favorable changes in serum insulin and IGF axis hormones relative to low-fat or Western diet. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17999389      PMCID: PMC3959866          DOI: 10.1002/pros.20683

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  33 in total

1.  Dietary patterns and risk of prostate cancer in Ontario, Canada.

Authors:  Melanie Walker; Kristan J Aronson; Will King; James W L Wilson; Wenli Fan; Jeremy P W Heaton; Andrew MacNeily; J Curtis Nickel; Alvaro Morales
Journal:  Int J Cancer       Date:  2005-09-10       Impact factor: 7.396

2.  The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone.

Authors:  Shoshana Yakar; Mary L Bouxsein; Ernesto Canalis; Hui Sun; Vaida Glatt; Caren Gundberg; Pinchas Cohen; David Hwang; Yves Boisclair; Derek Leroith; Clifford J Rosen
Journal:  J Endocrinol       Date:  2006-05       Impact factor: 4.286

3.  Dietary patterns and risk of prostate cancer in U.S. men.

Authors:  Kana Wu; Frank B Hu; Walter C Willett; Edward Giovannucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-01       Impact factor: 4.254

4.  Elevated circulating insulin-like growth factor binding protein-1 is sufficient to cause fetal growth restriction.

Authors:  Carole S Watson; Peter Bialek; Makoto Anzo; Javad Khosravi; Siu-Pok Yee; Victor K M Han
Journal:  Endocrinology       Date:  2005-11-17       Impact factor: 4.736

5.  Macronutrients, fatty acids, cholesterol and prostate cancer risk.

Authors:  E Bidoli; R Talamini; C Bosetti; E Negri; D Maruzzi; M Montella; S Franceschi; C La Vecchia
Journal:  Ann Oncol       Date:  2005-01       Impact factor: 32.976

6.  Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression.

Authors:  P Mukherjee; A V Sotnikov; H J Mangian; J R Zhou; W J Visek; S K Clinton
Journal:  J Natl Cancer Inst       Date:  1999-03-17       Impact factor: 13.506

7.  Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial.

Authors:  Michael L Dansinger; Joi Augustin Gleason; John L Griffith; Harry P Selker; Ernst J Schaefer
Journal:  JAMA       Date:  2005-01-05       Impact factor: 56.272

Review 8.  Dietary fat and prostate cancer: current status.

Authors:  L N Kolonel; A M Nomura; R V Cooney
Journal:  J Natl Cancer Inst       Date:  1999-03-03       Impact factor: 13.506

9.  Low-carbohydrate-diet score and the risk of coronary heart disease in women.

Authors:  Thomas L Halton; Walter C Willett; Simin Liu; JoAnn E Manson; Christine M Albert; Kathryn Rexrode; Frank B Hu
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

10.  Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial.

Authors:  Christopher D Gardner; Alexandre Kiazand; Sofiya Alhassan; Soowon Kim; Randall S Stafford; Raymond R Balise; Helena C Kraemer; Abby C King
Journal:  JAMA       Date:  2007-03-07       Impact factor: 56.272

View more
  70 in total

Review 1.  Diet and prostate cancer: mechanisms of action and implications for chemoprevention.

Authors:  Vasundara Venkateswaran; Laurence H Klotz
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

2.  Will metformin postpone high-fat diet promotion of TRAMP mouse prostate cancer development and progression?

Authors:  Hua Xu; Meng-Bo Hu; Pei-de Bai; Wen-Hui Zhu; Qiang Ding; Hao-Wen Jiang
Journal:  Int Urol Nephrol       Date:  2014-08-27       Impact factor: 2.370

3.  Effect of isocaloric low fat diet on prostate cancer xenograft progression in a hormone deprivation model.

Authors:  Jessica C Lloyd; Jodi A Antonelli; Tameika E Phillips; Elizabeth M Masko; Jean-Alfred Thomas; Susan H M Poulton; Michael Pollak; Michael Pollack; Stephen J Freedland
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

4.  Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo.

Authors:  Kristine Pelton; Christine M Coticchia; Adam S Curatolo; Carl P Schaffner; David Zurakowski; Keith R Solomon; Marsha A Moses
Journal:  Am J Pathol       Date:  2014-07       Impact factor: 4.307

5.  Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy.

Authors:  Kathryn N Phoenix; Frank Vumbaca; Melissa M Fox; Rebecca Evans; Kevin P Claffey
Journal:  Breast Cancer Res Treat       Date:  2009-11-22       Impact factor: 4.872

6.  Dietary intake and prostate cancer, continued pursuit for evidence.

Authors:  Pao-Hwa Lin; Stephen J Freedland
Journal:  Transl Androl Urol       Date:  2019-07

7.  Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study.

Authors:  Moran Artzi; Gilad Liberman; Nachum Vaisman; Felix Bokstein; Faina Vitinshtein; Orna Aizenstein; Dafna Ben Bashat
Journal:  J Neurooncol       Date:  2017-01-10       Impact factor: 4.130

8.  The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model.

Authors:  Jorge Caso; Elizabeth M Masko; Jean A Thomas Ii; Susan H Poulton; Mark Dewhirst; Salvatore V Pizzo; Stephen J Freedland
Journal:  Prostate       Date:  2012-10-04       Impact factor: 4.104

9.  Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience of Two Phase 1 Clinical Trials.

Authors:  Amir Zahra; Melissa A Fath; Emyleigh Opat; Kranti A Mapuskar; Sudershan K Bhatia; Daniel C Ma; Samuel N Rodman; Travis P Snyders; Catherine A Chenard; Julie M Eichenberger-Gilmore; Kellie L Bodeker; Logan Ahmann; Brian J Smith; Sandy A Vollstedt; Heather A Brown; Taher Abu Hejleh; Gerald H Clamon; Daniel J Berg; Luke I Szweda; Douglas R Spitz; John M Buatti; Bryan G Allen
Journal:  Radiat Res       Date:  2017-04-24       Impact factor: 2.841

10.  The ketogenic diet: uses in epilepsy and other neurologic illnesses.

Authors:  Kristin W Barañano; Adam L Hartman
Journal:  Curr Treat Options Neurol       Date:  2008-11       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.